Table 2.
Distribution of urinary biomarker concentrations among the ancillary study sample of LIBCSP women.
| Biomarker | LOD | n (%) <LOD | Median uncorrected urinary concentrations (μg/L)a |
Median creatinine-corrected urinary concentrations (μg/g creatinine)a |
||||
|---|---|---|---|---|---|---|---|---|
| With Breast Cancer (n=893) |
No Breast Cancer (n=650) |
Pb | With Breast Cancer (n=711) |
No Breast Cancer (n=598) |
Pb | |||
| 2,5-dichlorophenol | 0.2 | 3 (0.2) | 7.50 | 8.30 | 0.55 | 9.95 | 10.4 | 0.26 |
| Benzophenone-3 | 0.4 | 115 (7.5) | 8.60 | 10.1 | 0.39 | 11.5 | 11.9 | 0.40 |
| Bisphenol A | 0.4 | 282 (18.3) | 1.20 | 1.30 | 0.41 | 1.53 | 1.69 | 0.13 |
| Triclosan | 2.3 | 759 (49.2) | 2.40 | 2.40 | 0.52 | 5.18 | 5.77 | 0.64 |
| Methylparaben | 1.0 | 7 (0.5) | 104 | 100 | 0.24 | 160 | 150 | 0.37 |
| Propylparaben | 0.2 | 35 (2.3) | 25.6 | 22.4 | 0.13 | 39.9 | 34.8 | 0.36 |
| Butylparaben | 0.2 | 779 (50.5) | <LOD | 0.200 | 0.31 | 0.440 | 0.551 | 0.06 |
| Creatinine | 76.4 | 71.2 | 0.57 | |||||
Long Island Breast Cancer Study Project (LIBCSP) population-based women without breast cancer were frequency matched by age to women diagnosed with breast cancer between August 1, 1996 and July 31, 1997.
LOD, limit of detection (in μg/L)
a
Values <LOD were imputed as LOD/√2.
b
P-value for Wilcoxon rank-sum test.